Tositumomab
PharmacokineticsPharmacokinetics
| Anti-CD20 Monoclonal Antibody Pharmacokinetics [1] | ||||
|---|---|---|---|---|
| Parameter | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| Tmax (hr) | Tositumomab | 7.6 | Rituximab | Ibritumomab |
| Cmax (ng/ml) | Tositumomab | 167000 | 205800 | 67000 |
| Bioavailability (%) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| T1/2 (hr) | 64.8 | 68 | 206 | 108 |
| AUC (ng/ml/hr) | Tositumomab | 32939000 | Rituximab | 17000 |
| Clearance (L/h) | .078 | .017 | .009 | Ibritumomab |
| IC50 (nM) | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |
| Dosage | Tositumomab | 500 mg (4th Infusion) | 325 mg/m2 (4th Infusion) | Ibritumomab |
| Metabolism | Tositumomab | Ofatumumab | Rituximab | Ibritumomab |